Avacta Group plc (AVCT) Ordinary Shares 10p
2.00p
(3.77%)
- Add to watchlist
- Create an alert
- This stock can be held in a
2.00p
(3.77%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
2.00p
(3.77%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Avacta to start trialling second drug after FDA clearance
21 January 2026 12:33
(Sharecast News) - Avacta Therapeutics said on Wednesday that it has received clearance from the US Food and Drug Administration for the investigational new drug application for 'FAP-Exatecan', or...
-
Avacta reports strong operational progress
20 January 2026 13:52
(Sharecast News) - Avacta Group reported strong operational progress during 2025 on Tuesday as the clinical-stage biopharmaceutical company advanced its preCISION tumour-activated oncology platform,...
-
Avacta upbeat on fresh data from second oncology asset
18 December 2025 08:55
(Sharecast News) - Avacta reported new pharmacology data on its second oncology asset, FAP-Exd (AVA6103), on Thursday, showing sustained tumor exposure and prolonged responses across multiple preclinical...
-
Avacta reports 'clinically meaningful' tumour shrinkage in AVA6000 trial
17 December 2025 17:11
(Sharecast News) - Avacta Therapeutics said on Wednesday that new data from the phase 1b cohort of its ongoing trial of faridoxorubicin, also known as AVA6000, showed clinically meaningful tumour shrinkage...
-
Avacta presents promising findings to Boston conference
27 October 2025 09:07
(Sharecast News) - Shares in Avacta rose on Monday after the clinical stage biopharmaceutical company presented preclinical data showing its novel dual payload pre|CISION technology at a oncology conference...
-
Avacta raises £16m, releases solid clinical trial data
20 October 2025 09:01
(Sharecast News) - Avacta Group announced on Monday that it has raised £16m through an oversubscribed equity placing to accelerate development of its oncology pipeline, as new clinical data presented at the...
-
Avacta reports continued progress in second quarter
2 July 2025 11:03
(Sharecast News) - Avacta Therapeutics provided a second-quarter business update on Wednesday, reporting continued progress in its oncology pipeline and strengthening of its leadership team as it advanced...
-
Avacta posts narrower full-year losses from continuing operations
6 June 2025 12:25
(Sharecast News) - Avacta Group reported a reduced pre-tax loss of £28.98m from continuing operations in 2024 on Friday, down from £31.13m the year prior, as it accelerated its transformation into a...
-
Avacta pushes back annual results due to auditor delays
27 May 2025 08:58
(Sharecast News) - Life sciences company Avacta Therapeutics has announced that it has had to delay the release of its annual results by a week.
-
Avacta agrees to sell UK-based diagnostics unit
7 March 2025 09:26
(Sharecast News) - Life sciences firm Avacta revealed on Friday that it has agreed to sell its UK-based diagnostics unit to Duomed Belgium for £12.9m in cash.
-
Avacta reports promising results from ongoing clinical trial
16 January 2025 07:23
(Sharecast News) - Avacta Therapeutics announced promising results from its ongoing phase 1a trial of AVA6000 on Thursday, demonstrating meaningful tumour shrinkage in patients with salivary gland cancer (SGC).
-
Peel Hunt starts Avacta at 'buy' with 99p price target
21 November 2024 15:22
(Sharecast News) - Peel Hunt initiated coverage on Avacta on Thursday with a 'buy' rating and 99p price target as it pointed out three key aspects of the investment case.
Company announcements Announcements
-
FDA Clearance of IND Application for AVA6103
21 January 2026 07:00
Avacta Group
-
Year-end trading update
20 January 2026 07:01
Avacta Group
-
Appointment of Nominated Adviser & TVR
20 January 2026 07:00
Avacta Group
-
Avacta reports new AVA6103 pharmacology data
18 December 2025 07:00
Avacta Group
-
Faridoxorubicin Phase 1b SGC data
17 December 2025 07:00
Avacta Group
-
Preliminary Data in Faridoxorubicin Phase 1b Trial
8 December 2025 07:00
Avacta Group
-
Completion of Placing and TVR
3 November 2025 08:24
Avacta Group
-
Block Listing Six Monthly Return
27 October 2025 17:39
Avacta Group
-
Avacta presents preclinical data at AACR-NCI-EORTC
27 October 2025 07:00
Avacta Group
-
Equity fundraise of £16 million
20 October 2025 07:01
Avacta Group
-
Avacta Presents Phase 1a Data for Faridoxorubicin
20 October 2025 07:00
Avacta Group
-
Avacta to present data at EORTC-NCI-AACR
13 October 2025 07:00
Avacta Group
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2026. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.